Petrelintide
Also known as: ZP8396
3 notable studies · 3 references
TLDR
Petrelintide is an investigational long-acting amylin analogue being developed as a once-weekly obesity therapy, with encouraging early human evidence for weight reduction but without the large Phase 3, long-term safety, or clinical-outcomes evidence currently available for established incretin therapies.
Research Supports
- Studied as a once-weekly, long-acting amylin-receptor agonist for obesity and weight management
- Investigated for appetite/satiation signaling that is partly independent of the GLP-1 pathway
- Early studies examining body-composition (fat vs. lean mass) changes during treatment
- Investigated for gastrointestinal tolerability relative to incretin-based therapies
- Studied for its rationale in amylin-plus-incretin combination approaches
Observations Reported in Research
- Early clinical studies demonstrated dose-dependent body-weight reductions with once-weekly petrelintide
- Structural work on the related compound cagrilintide: it activates AMY1R, AMY2R, AMY3R, and CTR with distinct receptor conformations (Cao et al., 2025)
- REDEFINE 1 reported an estimated 20.4% average weight reduction at 68 weeks with cagrilintide plus semaglutide, informing but not establishing petrelintide combination rationale
- Large Phase 3 efficacy, cardiovascular-outcomes, and long-term safety data for petrelintide are not yet established
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Long-acting amylin analogue; investigational amylin receptor agonist
Petrelintide is a long-acting investigational amylin analogue being developed primarily for obesity and weight management. It belongs to the same rapidly developing therapeutic family as pramlintide (established short-acting amylin analogue), cagrilintide (long-acting amylin + calcitonin receptor agonist), eloralintide (long-acting preferential amylin-receptor agonist), and petrelintide (long-acting amylin analogue being developed as an obesity therapy). Petrelintide is being developed by Zealand Pharma, with Roche joining the program through a major development and commercialization partnership. The central research idea is whether amylin-based obesity treatment can produce substantial, durable appetite and weight effects while offering a different tolerability and body-composition profile from incretin therapies. Petrelintide remains investigational and is not FDA-approved.
What Is Petrelintide?
Petrelintide is an engineered analogue of the pancreatic hormone amylin. Natural amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells. Its physiological roles include signaling related to satiation, meal termination, food intake, gastric physiology, postprandial glucagon regulation, and glucose appearance following meals. The therapeutic potential of amylin signaling was established years ago with pramlintide. The problem with first-generation pramlintide is practicality: it is relatively short acting and historically requires frequent administration around meals. Petrelintide belongs to a newer generation designed to provide long-duration amylin signaling compatible with once-weekly treatment.
What Are Researchers Studying?
Obesity and body-weight regulation
Obesity is petrelintide's principal clinical-development target. Early clinical studies have demonstrated dose-dependent reductions in body weight following once-weekly administration. The important question now is whether these early effects remain substantial over much longer treatment periods and in larger randomized populations. Petrelintide has therefore progressed into a broader clinical-development program rather than remaining an early laboratory compound.
Appetite and satiation
Amylin is part of the body's physiological system for communicating that sufficient food has been consumed. Rather than primarily mimicking incretin hormones such as GLP-1, petrelintide attempts to leverage amylin-mediated satiation signaling. This gives researchers a pharmacological pathway that is partly independent of GLP-1. That distinction is important because two treatments can both reduce food intake while acting through different receptor systems.
Amylin-based obesity treatment independent of GLP-1
One of petrelintide's most interesting roles is as a potential non-incretin obesity therapy. Most of the recent obesity-drug revolution has centered on GLP-1, GIP, and glucagon. Petrelintide instead targets the amylin system. That creates the possibility of treating obesity through a substantially different hormonal pathway. It also makes petrelintide interesting for people who may not tolerate or respond adequately to incretin-based therapies, although clinical evidence establishing such a role is not yet available.
Lean mass and body composition
Body composition is becoming an increasingly important endpoint in obesity-drug development. Weight loss consists of both fat mass and fat-free/lean mass. Researchers are therefore interested not only in how much weight an obesity therapy removes, but what tissue accounts for that weight. Petrelintide's development program has generated particular interest in whether amylin-based therapy may produce favorable fat-to-lean-mass changes. This remains an emerging research area and should not yet be turned into the broad claim that petrelintide “preserves muscle.” The appropriate wording is: Researchers are investigating whether the body-composition pattern during petrelintide-associated weight reduction differs meaningfully from other obesity therapies.
Gastrointestinal tolerability
Nausea, vomiting, diarrhea, and other gastrointestinal adverse events are common limitations of several modern obesity medications. Developers of petrelintide are investigating whether amylin pharmacology can provide substantial appetite and weight effects with a tolerability profile that differs from incretin-based therapies. Early studies are encouraging enough to justify larger trials, but cross-trial comparisons are unreliable. A trial reporting less nausea than a separate semaglutide or tirzepatide trial does not prove that petrelintide is better tolerated. A proper randomized head-to-head comparison would be needed.
Combination therapy
Amylin signaling is mechanistically complementary to incretin signaling. That raises an obvious research possibility: amylin pathway + GLP-1/incretin pathway, rather than increasing activity at the same receptor indefinitely. CagriSema already provides clinical proof that combining amylin-related pharmacology with GLP-1 receptor agonism can produce substantial weight reduction. REDEFINE 1 reported an estimated 20.4% average weight reduction at 68 weeks with cagrilintide plus semaglutide. That result does not establish efficacy for petrelintide combinations, but it provides strong biological justification for studying complementary amylin/incretin strategies.
How Does It Work?
Petrelintide attempts to reproduce and prolong amylin signaling. Amylin receptors are unusual because they are not encoded as simple standalone receptors. Instead, an amylin receptor is formed when the calcitonin receptor (CTR) associates with a receptor activity-modifying protein (RAMP). Different RAMPs produce different receptor subtypes: CTR + RAMP1 → AMY1R; CTR + RAMP2 → AMY2R; CTR + RAMP3 → AMY3R. These receptors participate in neural pathways involved in satiation and energy intake. This is also why Aminodex shouldn't treat every “amylin analogue” as pharmacologically identical. Recent structural work with cagrilintide demonstrates just how differently engineered peptides can interact with AMY receptors and CTR. Cagrilintide activates AMY1R, AMY2R, AMY3R and CTR and produces distinct receptor conformations. Petrelintide's precise receptor pharmacology and how it translates into clinical differences remain active areas of investigation.
What Does the Research Show?
Human research
Petrelintide has progressed into human clinical development, but its evidence base remains considerably less mature than semaglutide, tirzepatide, or even cagrilintide. The important hierarchy is: Human weight-loss signal: demonstrated. Large Phase 3 efficacy: not yet established. Cardiovascular-outcomes evidence: not established. Long-term morbidity/mortality benefit: not established. That makes petrelintide promising but still distinctly investigational. Early human results can be genuinely interesting without being presented as though they carry the same evidentiary weight as SELECT, SURMOUNT, or other large Phase 3/outcomes programs.
Animal research
Preclinical amylin research has established strong biological plausibility for targeting this system in obesity. Amylin-related signaling affects meal size, satiation, food intake, gastric physiology, glucagon regulation, and energy balance. Petrelintide's preclinical development contributed to its selection as a long-acting amylin candidate suitable for human testing. However, as the clinical program expands, direct human evidence should increasingly take priority over animal findings in the Aminodex profile.
In-vitro research
Cellular studies are important for characterizing how engineered amylin analogues interact with AMY1R, AMY2R, AMY3R, and CTR, and for comparing signaling potency, receptor selectivity, duration of action, and structural behavior. This area has become especially important because recent structural research demonstrates that compounds grouped casually as “amylin analogues” can interact differently with this receptor family.
Notable Studies
Structural and Dynamic Features of Cagrilintide Binding to Calcitonin and Amylin Receptors
humanStructural and dynamic characterization of cagrilintide binding to calcitonin and amylin receptors. Cagrilintide activates AMY1R, AMY2R, AMY3R and CTR and produces distinct receptor conformations. This structural work shows that engineered peptides grouped casually as amylin analogues can interact differently with this receptor family.
Limitations: This is structural receptor pharmacology for cagrilintide, not a clinical trial of petrelintide. It does not establish petrelintide receptor selectivity or clinical effects.
View publication →Structural and Mechanistic Insights Into Dual Activation of Cagrilintide in Amylin and Calcitonin Receptors
humanStructural and mechanistic insights into dual activation of cagrilintide at amylin and calcitonin receptors. Supports the point that amylin analogues should not be treated as pharmacologically identical.
Limitations: Structural/mechanistic work on cagrilintide, not a petrelintide clinical result. Does not establish petrelintide clinical efficacy, safety, or tolerability.
View publication →Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial
humanPhase 2 comparison of once-weekly cagrilintide for weight management. Provides comparison with established long-acting amylin pharmacology. REDEFINE 1 (cagrilintide plus semaglutide) reported an estimated 20.4% average weight reduction at 68 weeks; that result does not establish efficacy for petrelintide combinations but provides biological justification for studying complementary amylin/incretin strategies.
Limitations: This is a cagrilintide trial, not a petrelintide trial. Cross-trial comparisons of weight loss or nausea are unreliable. A proper randomized head-to-head comparison would be needed before claiming petrelintide is better tolerated than semaglutide or tirzepatide.
View publication →What We Still Don't Know
A lot—and that's central to this profile. Researchers still need to establish: Magnitude of weight reduction over 1+ years; Durability of weight reduction; Effects after discontinuation; Long-term safety; Cardiovascular outcomes; Effects on cardiovascular mortality; Diabetes-related outcomes; Effects on liver disease; Kidney outcomes; Long-term gastrointestinal tolerability; Whether body-composition changes differ meaningfully from incretin therapies; Whether lean mass is better preserved; Whether amylin pharmacology provides advantages for people who do not tolerate GLP-1 drugs; Comparative efficacy versus semaglutide; Comparative efficacy versus tirzepatide; Comparative efficacy versus cagrilintide; Comparative efficacy versus eloralintide; Whether combining petrelintide with incretin therapies provides additive benefit; Which amylin-receptor subtypes account for its clinical effects; Whether receptor pharmacology translates into meaningful tolerability differences. Those aren't small gaps. They are the difference between an interesting clinical candidate and an established obesity treatment.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Petrelintide research with you.
Get the Aminodex Petrelintide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Cao J, Belousoff MJ, Johnson RM, et al. Structural and Dynamic Features of Cagrilintide Binding to Calcitonin and Amylin Receptors. Nature Communications. 2025;16:3389. doi:10.1038/s41467-025-58680-y. https://pubmed.ncbi.nlm.nih.gov/40204768/
- Gu YM, Yuan QN, Li X, et al. Structural and Mechanistic Insights Into Dual Activation of Cagrilintide in Amylin and Calcitonin Receptors. Acta Pharmacologica Sinica. 2026;47:162–172. doi:10.1038/s41401-025-01635-2. https://pubmed.ncbi.nlm.nih.gov/40847076/
- Lau DCW, Erichsen L, Francisco AM, et al. Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial. The Lancet. 2021;398:2160–2172. doi:10.1016/S0140-6736(21)01751-7. https://pubmed.ncbi.nlm.nih.gov/34798060/
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.